To use all functions of this page, please activate cookies in your browser.
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Nelarabine
Nelarabine is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. It was previously known as 506U78. Product highlightNelarabine is a purine nucleoside analog converted to its corresponding arabinosylguanine nucleotide triphosphate (araGTP), resulting in inhibition of DNA synthesis and cytotoxicity. Pre-clinical studies suggest that T-cells are particularly sensitive to nelarabine. In October 2005, it was approved by the FDA for T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma that has not responded to or has relapsed following treatment with at least two chemotherapy regimens. Complete responses have been achieved with this medication. It is marketed as Arranon by GlaxoSmithKline. |
||||||||||||||||||||||||||||||||||||||||||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Nelarabine". A list of authors is available in Wikipedia. |
- Silicone specialities: WACKER builds new production site in the Czech Republic - The investment volume is in the low triple-digit million-euro range
- Predicting the Performance of Catalysts - Award for Electrochemist
- Simpler and safer method for handling a useful but foul-smelling gas in chemical synthesis
- Superconductivity: New tricks for finding better materials - Nickelates are a new promising material for future superconductivity technologies: Scientists have now succeeded in explaining their electronic structure.
- MWG-Biotech’s RoboSmart: The first fully automated system for complete DNA purification up to sequencing reaction